Obesity and male hypogonadism are both associated with one another. Moreover, male hypogonadism can serve as a risk factor for obesity while obesity can serve as a risk factor for male hypogonadism. There has been little research regarding obesity and its reduction on that of gonadal function. Lifestyle factors as well as other factors have been attributed to the development of obesity which can induce gonadal dysfunction. Therefore, the treatment of male hypogonadism is of great interest for both providers and patients. The future of hypogonadism therapy may exist with the development of aromatase inhibitors that can minimize undesired effects and allow the benefits of androgens. Testosterone treatment can lead to compromised fertility and addiction. Aromatase allows for the peripheral conversion of androgens into estrogens resulting in the inhibition of gonadotropin production. Therefore, aromatase inhibitors can be used instead to increase gonadotropin secretion. There is growing evidence that aromatase inhibitors can improve the fertility and raise testosterone levels.
Introduction
There is an increased prevalence of hypogonadism in the male population that has been described in several studies. A consistent theme among these studies is that as men age, hypogonadism increases. Physicians often prescribe testosterone to obese men with hypogonadism; however, it is wiser to provide aromatase inhibitors to prevent this instead. Also, patients may become addicted to testosterone, and eventually physiological response such as libido and erectile dysfunction (ED) will gradually decline due to high aromatase activity. Therefore, patients may become refractory to testosterone treatment.
Methodology
An extensive search was performed on PubMed and MEDLINE for any published literature on the role of aromatase in adult male for obesity-associated hypogonadism. Although there was no date restriction on the search, we placed an emphasis on the past 5 years. No specific exclusion criteria were set. Publication quality was assessed using the relative citation ratio derived from iCite bibliometrics. We selected papers that revealed information regarding the physiology of androgen and aromatase production, obesity and aromatase function regarding hypogonadism, aromatase inhibitors, other treatment modalities for obesity-induced hypogonadism, complication of androgen replacement on prostate, and addiction to anabolic steroids.
Results and Discussion

Physiology of androgen production
Male androgen production is managed by the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary gland. The process begins with the hypothalamus secreting gonadotrophin releasing hormone (GnRH) into the portal blood leading to the anterior pituitary gland. In response to GnRH, the anterior pituitary gland releases both FSH and LH into the bloodstream to be transported to the testes [1, 2] .
Within the interstitial space surrounding the seminiferous tubules, the Leydig cells will secrete androgen and testosterone, in response to stimulation caused by LH [1] . The enzyme 5α-reductase converts testosterone found in the adrenal glands, prostate, hair follicles, and testes into dihydrotestosterone (DHT). A negative feedback loop between the testes and the pituitary gland manages androgen production to stay within normal physiological levels [3] . High levels of DHT or testosterone sensed by the anterior pituitary gland diminish LH surge to downregulate testosterone and DHT levels [2] .
FSH stimulates the Sertoli cells within the seminiferous tubules causing the secretion of androgen-binding protein (ABP). ABP binds with testosterone within the seminiferous tubules to promote spermatogenesis. ABP is known to also link with DHT and 17-beta-estradiol. A majority of testosterone not bound to ABP would be bounded to sex-hormonebinding globulin (SHBG). [3] Remaining testosterone not bound to ABP or SHBG circulates the blood in an unbound form to either be transferred to the tissues or converted into an inactive form that will eventually be secreted [2] . A small percentage of testosterone will be converted into estradiol by the enzyme aromatase cytochrome P450 [2] . The generated sperm cells will be found in the lumen of the seminiferous tubules. The Sertoli cells also secretes inhibin in response to FSH stimulation. Inhibin acts as a negative feedback signal to the anterior pituitary gland. High levels of inhibin cause the anterior pituitary gland to decrease the rate of FSH secretion, resulting in the decrease of Sertoli cell stimulation and spermatogenesis [4] .
Hypogonadism
Male hypogonadism is the failure to produce sufficient testosterone for physiological use. Hypogonadism is commonly found in older males due to their age being a natural detriment in testosterone production. Males with HIV and obesity also seem to prone to hypogonadism [5] [6] [7] [8] . Testosterone is a vital steroid for males as it plays roles in vast physiological functions such as testicular function, hair growth, nitrogen retention, development of bone density, development and distributing muscle mass, metabolism of fat, development of secondary sexual characteristics, and psychological factors dictating personality such as aggression, self-esteem, and motivation [1, [5] [6] [7] [8] [9] [10] . A significant decrease in testosterone, such as one due to hypogonadism, significantly decreases the quality of life since multiple physiological mechanisms will not be operating at normal levels.
Hypogonadism can occur as early fetal development. A genetically male child with hypogonadism may be born with either underdeveloped genitals, ambiguous genitals, or even female genitals [9, 10] . This can be explained due to dihydrotestosterone (DHT), a converted form of testosterone, which is vital in external genitalia development for males. A shortage of DHT may disrupt male sexual development before birth. Hypogonadism that occurs in males at pubertal ages may experience a delay or complete lack of puberty and development. Individuals would experience impaired penis and testicular growth, disproportionate limb growth in respect to their torso, impaired growth or lack of body and facial hair, failure in deepening of their voice, decrease in muscle mass development, and gynecomastia (development of breast tissue) [9] [10] [11] [12] [13] .
The effects on adult males range from psychological to emotional and sexual, the most effected attribute of life disturbed by acquiring hypogonadism. Individuals exhibit a decrease in bone mineral density, muscle mass, body and facial hair, osteoporosis, gynecomastia, hot flashes, depression, lack of interest, difficulty concentrating, accumulation of fat, temporal hair recession, lack of a deepened voice, and loss of aspects gained during puberty [9, 10, 14] . These symptoms can also be seen concurrently with the sexual side effects of hypogonadism found in Table 1 .
The causes of hypogonadism can be differentiated into two types known as primary hypogonadism and secondary hypogonadism. Primary hypogonadism involves disease or damage done to the seminiferous tubules themselves. Individuals experiencing primary hypogonadism have high concentrations of FSH and LH and/or low concentrations of serum testosterone and/or sperm count [3, 8, [15] [16] [17] . Damage to the seminiferous tubules can lead malfunction of the Leydig and Sertoli cells' production of testosterone and inhibin, Tables 2 and 3 .
Secondary hypogonadism suggests that disease or damage has occurred to either the hypothalamus or the pituitary gland. Individuals experiencing secondary hypogonadism have either low or normal concentrations of FSH and LH and/or low concentrations of serum testosterone and/or sperm count [3, 8, [15] [16] [17] . Damage to the hypothalamus or the pituitary gland can result in the malfunction of the negative feedback loop with the tests resulting in the inability to differentiate whether rate of FSH and LH should be increased or not. Another effect of such damage would be the inability of the hypothalamus to determine when to release GnRH causing fluctuations in FSH and LH [17] [18] [19] . A list of common diseases and conditions causing secondary hypogonadism can be found in Table 2 .
Both types of hypogonadism can be either a congenital trait or acquired throughout life [3, 5-8, 15, 16] . It is also possible for both types to occur at the same time. Laboratory testing and imagery are required in order to properly differentiate between primary and secondary hypogonadism during diagnosis such as a dedicated pituitary MRI for secondary hypogonadism [14] . Testicular imaging would be used in the case of primary hypogonadism [14] .
The primary symptom is a very low concentration of free serum testosterone which is shared among a myriad of diseases, conditions, and psychosexual issues. Due to this massive overlap, physicians should take final consideration and caution when finalizing a diagnosis of hypogonadism. Diagnosis of hypogonadism requires measuring serum testosterone levels, sperm count, FSH concentration, and LH concentration of the patient in question [3, 7, 8, 15] . During sperm analysis, motility of the sample is also taken into consideration as an appropriate percentage of the sperm should be motile [16, 17] .
The serum testosterone level takes precedence over the other tests since low levels of testosterone is defining of hypogonadism. Normal levels of testosterone in adult males range between 300 and 800 ng/dL. A value less than 300 ng/ dL is an initial indicator for hypogonadism [3, 7, 8] . The serum testosterone should be taken between 8:00 a.m. and 10:00 a.m. since testosterone levels fluctuate throughout the day, with the highest testosterone production occurring in the early morning. The volume extracted should be approximately 70% of total testosterone volume available [3, 7, 8] . Abnormities regarding SHBG may void the value of an evaluation of a serum testosterone evaluations since more produced testosterone will be left in its unbound form. In a scenario where a patient is presumed to have hypogonadism while experiencing a malfunction with their SHBG, free serum testosterone level should be measured and compared to their serum testosterone level [10, 14] .
Physiology and genetics of aromatase
The enzyme aromatase, through a series of biochemical processes, converts free testosterone into 17 β-estradiol (E2) and androstenedione into estrone when these substrates bind to its heme cavity [1, [20] [21] [22] . This enzyme is typically found in the cytoplasm or the endoplasmic reticulum where it is regulated by tissue specific promoters. [1, 20, 21] The regulation of aromatase involves tissue-specific promoters which are regulated by cytokines, hormones, and other external factors. In males, aromatase resides in various tissues such as in the brain, adipose tissue, gonads, blood vessels, skin, placenta, and bone [1, [20] [21] [22] . Extraglandular aromatization results as the major source of estrogens within male; for this reason, aromatase activity dictates endocrine, autocrine, and paracrine effects on certain tissues targeted by estrogens [22] .
The aromatase enzyme is a component of the cytochrome P450 system, the system that regulates the conversion of estrogens from androgen precursors, and is encoded by the CYP19A1 gene located on chromosome 15q21.2 [22] . This gene has a coding region of 30 kilobases (kb), a regulatory region estimated to be at least 93 kb, ten coding exons (II-X), and upstream 5′ noncoding exons, also known as exon Is [21, 23] . Tissue-specific regulation is possible due to the exon Is each having an exclusive upstream promoter sequence responsible for alternative tissue-specific activity [21] . Examples of tissue-specific regulation can be examined with the expression of promoter PII uniquely found in the gonads [38] . Exon f is expressed in the brain while exon I.4 is expressed in adipose tissue. Both of these exons are found upstream of PII [38] .
In the literature, eight males with aromatase deficiency have been reported that had deficient levels of estradiol. [28] [29] [30] [31] [39] [40] [41] [42] . An unfused epiphysis leading to linear growth into adulthood, a low bone mass, and aboveaverage body length was shown by these men. Testicular s i z e i n t h e s e m e n r a n f r o m m i c r o o r c h i d i s m t o macroorchidism and the plasma testosterone levels differed generally in accordance with testis size. Levels of luteinizing hormone (LH) were either elevated or normal. Once treated with estradiol, disturbances in the lipid profile improved in most of these patients, BMD increased, and epiphyses closed.
On the other hand, instances of aromatase excess regarding familial cases have been reported. Aromatase excess syndrome (AEXS), formerly known as familial gynecomastia, is a rare genetic disease characterized by the pre-or peripubertal onset of gynecomastia. As a result of overexpression of aromatase, individuals with AEXS experience symptoms associated with hyperestrogenemia due to the increased conversion of androgens into estrogens. Other symptoms include heterosexual precocity, prepubertal gynecomastia, hypogonadism, micropenis, advanced bone maturation, and short final stature. The cause of this disease has been hypothesized to be an inheritable autosomal dominant genetic mutation of CYP19A1. A theme of premature bone maturation and gynecomastia are associated with high peripheral estrogen synthesis. Stratakis et al. described a situation in which an abnormal high expression of an alternative first exon was caused by aromatase excess sydnrome [32] . In addition, Shozu et al. described a situation in which the aromatase gene was placed adjacent to cryptic promoter in a case caused by chromosomal rearrangement [33] .
These case reports delineate the vital commitment of estrogens to male wellbeing and distinguish the conceivable signs and dangers of aromatase-inhibitor treatment in men. Gynecomastia can be prevented by using an aromatase inhibitor. They might be utilized to expand gonadotropin discharge and along these lines empower Leydig and Sertoli cell function. Aromatase inhibitors might be utilized to defer or avoid epiphysial closure and thereby increase adult height. A noteworthy concern of aromatase inhibition is the possible detrimental effect on bone mineralization [34] .
Obesity and aromatase function regarding hypogonadism
Obesity has become a prevalent problem for the overall health of men in the modern world. An inverse relationship exists between obesity and testosterone levels leading to a plethora of sexual issues. Many studies confirm that increased obesity in males increases the risk of hypogonadism [35, 36, [43] [44] [45] . However, the exact mechanism behind this association is still under considerable consideration. Excess aromatase function may be the cause of this relationship as a result of low testosterone levels left from the increased rate of conversion into estradiol. These varied levels of estradiol and testosterone alter fat distribution, adipocyte differentiation, and proliferation. Adipose tissue primarily serves to store triglycerides. However, this tissue has been observed to influence the hypothalamic-pituitary-gonadal axis through its ability to secrete several hormones into the body via the bloodstream.
Mammals exhibit two types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). Brown adipose tissue stores triglyceride to convert to heat energy for thermogenesis. This physiological function of fat to heat conversion occurs in times where energy expenditure is needed when experiencing situations where food is scarce and predominantly in situations where heat must be generated in order to combat cold. White adipose tissue is responsible for the energy storage in the form of triglycerides. Lipases convert these triglycerides into fatty acids and glycerol. In situations of energy depletion, lipolysis will release the fatty acids stored in white adipose tissue into the plasma to catalyze energy generation. Obese males exhibit a high level of white adipose tissue. Another character of white adipose tissue is the secretion of adipose-derived hormones, adipokines, and increased aromatase activity. The excess aromatase increases the rate of conversion of androgens into estrogens such a testosterone into estradiol. Obese males may be left with low physiological levels of testosterone. Elevated levels of estradiol are hypothesized to interact with the negative feedback loop of the hypothalamic-pituitary-gonadal axis. With increased estradiol, being an indicator of excess testosterone, LH secretion would decrease causing an overall decrease in testosterone production [37] . Support for this hypothesis is seen with the use of aromatase inhibitors restoring testosterone, LH, FSH, and serum estradiol to normal physiological levels [46] . This mechanism proposes that excessive aromatase activity within obese males causing a testosterone-estradiol shunt would lead to hypogonadotropic hypogonadism (secondary hypogonadism).
The contribution of leptin has also been noted to the manifestation of hypogonadism within obese males. Leptin, a pleiotropic cytokine-like hormone, has been found to have a positive relationship with adiposity [47] . Excess leptin has been observed to cause oxidative damage to the Leydig cells themselves resulting in a disruption of steroidogenesis, which would be a cause of primary hypogonadism [48] . Besides the oxidative damage to the Leydig cells, the testosteroneestradiol shunt (due to excess aromatase activity) is a major contributor to obesity-induced hypogonadism.
Physiological low testosterone levels have been noted to cause the accumulation of adipose tissue [8] . As mentioned before, symptoms of hypogonadism include a decrease in muscle mass, decrease in bone mineral density, and an accumulation of fat. Other symptoms of hypogonadism that relate to obesity include insulin resistance and an excessive lipoprotein lipase activity. Obesity-induced hypogonadism may trigger a problematic cycle where obesity reinforces an individual's hypogonadism while their hypogonadism will reinforce their obesity.
Management
Aromatase inhibitors
Aromatase inhibitors are classified as first, second, or third generation or as either nonsteroidal or steroidal [105] . Aromatase activity is inhibited by steroidal inhibitors such as formestane and exemestane by resembling the substrate androstenedione [106] . Nonsteroidal enzyme inhibitors (anastrozole and letrozole) restrict enzyme activity by binding with the heme iron of the enzyme [107] . First-generation aromatase inhibitors are considered to be nonspecific and weak. They require adrenal supplementation as they can block other steroidogenic enzymes. Third-generation inhibitors do not hinder related enzymes and are potent.
Use of aromatase inhibitors can ease gynecomastia within 6 months and are possibly useful to prevent recurrence of gynecomastia after reduction mastoplasty. It also promotes virilization and increased testicular volume [49] [50] [51] .
Aromatase inhibitors joined with agonists of gonadotrophin-releasing hormone was sufficient for the prevention of premature epiphysial closure in young men with pubertas praecox of different etiologies [34] . Aromatase inhibitors can be used in boys who are short in height and those who have a delay of puberty in order to increase adult height. Aromatase inhibitors do not work well for the treatment of gynecomastia in pubertal boys. They also have limited use for the prevention of gynecomastia in bicalutamide-treated men with prostate cancer. There is no consistent evidence for a beneficial effect on spermatogenesis even though aromatase inhibitors increase FSH levels [34] . Aromatase inhibitors may come as an alternative for traditional testosterone supplementation to improve testosterone levels for older men with late-onset hypogonadism. It still remains controversial of higher testosterone levels in older men and its longterm benefits associate with it. Also, it is still uncertain if the amount of testosterone can be stimulated by aromatase inhibitors for men who had low levels of testosterone [34] .
Although selective aromatase inhibitors are relatively safe, symptoms, such as bone fracture and arthralgia, have been reported following long-term use in women with breast cancer [52] . Through sex steroid therapy, male and female bone may respond differently. It is unpredictable whether side effects that occur in females also affect males with testosterone levels elevated by the use of aromatase inhibitors [21] . No detrimental effects on bone metabolism have yet been reported in males due to long-term use of aromatase inhibitors [53] . Side effects of aromatase inhibitor use in men have not however been determined [54] .
Other treatment modalities for obesity-induced hypogonadism
For all hypogonadal men, replacement of testosterone is indicated except in patients where fertility is desired or when there are contraindications. The goal of testosterone therapy is to succeed in the development of secondary sexual characteristics as well as help trigger puberty. It is also intended to raise average serum testosterone levels into the mid-normal range which is around 400-700 ng/dl. When testosterone levels are back to the normal range in younger hypogonadal men, it allows for an improved sexual function such as erectile function and libido. There is a controversy regarding whether testosterone has the ability to improve ED without the effects on libido [55] [56] [57] [58] [59] [60] . There is an increase in bone mineral density in younger and older men with hypogonadal as an effect of testosterone replacement therapy [61] [62] [63] [64] [65] [66] [67] [68] [69] . It was recently found that there is a decrease in waist circumference and body weight in long-term testosterone replacement therapy [70, 71] . While the significant weight loss requires careful confirmation, randomized controlled trials showed that testosterone replacement therapy reduced body fat mass, regional fat distribution, and waist circumference in hypogonadal men with and without obesity [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] . Individuals with hypogonadism and metabolic syndrome or type 2 diabetes have reported slight improvements in insulin sensitivity, hemoglobin A1C as well as a decrease in central adiposity [35, 77, 78, [81] [82] [83] [84] [85] [86] .
The development of increased oiliness of skin and acne are common adverse events of testosterone replacement therapy because of the androgenic effects on the sebaceous gland [5] . Several major harmful effects are an increase in hemoglobin, hematocrit, and red cell indices [87] . An increased risk of cardiovascular events in older men showed to be more prevalent in a recent meta-analysis with testosterone treatment. The increase cardiovascular event risks were higher in non-pharmaceutical-supported compared to industry-supported studies [88] . There was no increase in prostate cancer or prostatic hyperplasia in the meta-analysis of placebo-controlled clinical trials [87] Testosterone replacement in hypogonadal men does not increase the risk of voiding symptoms of benign prostatic hyperplasia [89] but may increase prostate size to that of eugonadal men [90] .
Impact of weight loss and loss of abdominal fat on testosterone
Weight loss is related to testosterone therapy, and obesity is related to reduced testosterone levels. Some mechanisms for low testosterone in obesity complex mechanisms are increased levels of sex hormone-binding globulin, androgen resistance, insulin resistance, and low levels of luteinizing hormone. The number of adipocytes and visceral fat is enhanced with the loss of androgen receptor function. The normalization of physiological testosterone levels reduces the activity of lipoprotein lipase and triglycerides [95] .
Complication of androgen replacement on prostate (BPH)
Currently, there has been no review or study that shows the risk of prostate cancer associated with men undergoing testosterone replacement therapy. This is a question that has yet to be answered. In a study with men who have prostatic intraepithelial neoplasia (PIN) did not show an increased risk of prostate cancer even though they are at a high risk for prostate cancer [87] . An explanation that testosterone produces effects that do not alter intraprostatic androgen levels. This was seen through a study by Marks et al., a double-blind study that involved men with hypogonadism who were given testosterone every 2 weeks for 6 months [100, ] . The results showed that the levels of DHT and testosterone increased in the serum, but no change in the hormones by prostate biopsy. ED androgen replacement does not worsen urinary retention and lower urinary tract symptoms (LUTS). However, prostate size is shown to increase by 12 percent in accordance with testosterone supplementation [101] . In some studies, the use of androgen replacement has shown an improvement in LUTS. In a randomized controlled trial conducted by Shigehara et al., fifty two men were assigned to recieve androgen replacement therapy [103, 102] . Only twenty three men had improvements with maximal urinary flow rates as well as IPSS compared with controls. It is important to note that the increase in prostatic hypertrophy in elderly men not on androgen replacement therapy dos not differ with the increase in prostate size of men on androgen replacement therapy. Altogether, men diagnosed with benign prostatic hyperplasia is not contraindicated with androgen replacement and and does not drastically worsen LUTS [86] .
Adverse effects of androgen replacement therapy
There are generally few if any side effects when restoring testosterone back to physiological levels. In boys around puberty, the increased testosterone levels stimulate erythropoiesis so there are higher hemoglobin levels in adult males compared to females [91] . Therefore, it is suggested that the decrease in hemoglobin is secondary to the declining levels of testosterone. Testosterone replacement is used for hypogonadal men with anemia [91] . It is essential that the hemoglobin levels be brought back to normal levels but not past physiological range which may lead to a blood viscosity that could cause thrombosis [91] .The Endocrine Society recommends for men who have a baseline hematocrit below 50 should not be administered testosterone replacement in worry of erythropoiesis. It is seen that the occurrence of erythropoiesis is related with the dosage of testosterone administered [91] . A double-blind study demonstrated that using IM testosterone may influence thromboxane A2 (TXA2) which is a platelet pro-aggregatory agent as well as a vasoconstrictor. This may contribute to RBC adhesion of androgenic steroids and thrombogenicity. It is to be noted that the patients were not testosterone deficient all the way to baseline and the sample size was small. [91] Addiction to anabolic steroids Anabolic androgenic steroids are pharmacological and chemical derivatives of testosterone. The active molecules are 5 adihydrotestosterone (DHT) and testosterone which are characterized by 3-oxo groups and 17-B hydroxyl groups [92] . There is a nuclear receptor superfamily that the activity of androgens is mediated by. The receptor is characterized by two transcriptional domains AF-1 and AF-2 and a DNA binding domain. The hormone binds to the receptor ligand-binding domain after it reaches the target cells. The receptor becomes active when it is dissociated from protein chaperones where it translates from the cytoplasm to the nucleus. The androgen response element on the chromatin interacts with the activated receptors and triggers the formation of a transcriptional complex [92] . For nuclear-receptor-mediated transcriptional regulation, co-activator and co-repressor complexes are in cells which promote translation, gene activation, transcription, and an alteration in cell function. Since the androgens are steroid hormones, they are transported around in the circulation by binding to plasma proteins [92] . A transport portion that has high affinity for testosterone is SHBG which binds around 60% of hormones transported in the blood. Albumin has a high plasma concentration and is important for steroid hormone metabolism [92] .
There have been chemical modifications done to testosterone. For example, stanozolol was synthesized from oxymetholone. Its purpose is for doping since it has anabolic properties. Nadrolone is a hormone produced in females during pregnancy in small quantities. It resembles the metabolism of testosterone. When the methyl group to the carbon atom at position 19 is substituted with a hydrogen atom, the ratio of the anabolic and androgenic activities change [92] .
Many people who are addicted to anabolic steroids and those who abuse them will often use them in cycles. They try to avoid the negative side effects from the drugs by going on and off from them. The body becomes physically dependent on the drugs when taken in a 6-12-week cycle [93] . When a user decides to take a withdrawal period, hormonal imbalances caused by steroids make it dangerous for the user. The symptoms are a psychological withdrawal as well as headaches and muscles cramps (physical withdrawal symptoms). In a study conducted with 49 males, the common withdrawal symptoms experienced were fatigue, depressed mood, restlessness, anorexia, decreased libido, and insomnia [94] .
Prostatic hyperplasia It is believed that young hypogonadal males treated with testosterone leads to a significant growth of the prostate. This was reported in men who had primary hypogonadism. In a study, 13 men with Klinefelter's sydnrome who were between the ages 25 and 32 years old were administered intramuscular testosterone found an increased size of the prostate [96] . In the majority of studies, however, the effect of exogenous androgens on prostatespecific antigen or prostate volume showed no effect for older hypogonadal men [96] . Forty-four late-onset hypogonadal men in a randomized controlled trial had found that those treated with testosterone replacement therapy had no increase in prostate tissue levels of DHT or testosterone even though there were increased levels of serum testosterone. From the years 1941 to 2008, Morgentaler and Traish had a theory called the "saturation model" to demonstrate that the lack of influence that testosterone replacement therapy has on prostate volume or prostate-specific antigen in these men [96] . They believed that androgen concentration is not affected by the prostate at normal levels or even in mild hypogonadism since the AR is saturated by androgens; this would then mean that the maximum androgen-AR binding has been reached. On the other hand, testosterone does become sensitive changing levels of androgen and low amount of testosterone. Another concept is the development of benign prostatic hyperplasia in older men does not rely on testosterone but the aromatization of androgens to estrogens. It then binds to estrogen receptors in the prostate and bladder [96] This concept was evident in a study conducted by Schatzl et al. with men over the age of 40 which showed that the increasing prostate volume correlated with increasing estrogen levels and increasing serum testosterone did not [102, 96] .
Cardiovascular disease There have been recent studies that show a correlation with exogenous testosterone use with adverse cardiovascular outcomes, but there is also an equal amount of studies that demonstrate the exact opposite. Therefore, at present, this issue remains controversial. Some of the reasons why this may be being that there are differences in trials with inclusion and exclusion criteria [97] . For instance, age, underlying cardiovascular risk factors, degree of clinical hypogonadism, baseline T levels, and patient mobility [97] .
It was previously believed that androgens could have an atherogenic effect since as men aged, there was also an increased incidence of cardiovascular disease (CVD) than compared to aging women. Through androgen administration, there could be an even higher risk of CVD since aging men had already higher levels of testosterone. Recently, several studies have found that testosterone replacement therapy may have beneficial or neutral effects on cardiovascular risk factors and complications. Meta-analyses that have been published between 2005 and 2010 have shown that with testosterone replacement therapy (TRT) had no impact on the major cardiovascular events but it did increase hemoglobin as well as hematocrit [97] . Testosterone replacement therapy does have a risk of leading to edema and water retention. There still needs to be longitudinal studies that will help us understand coronary artery changes and the effects of testosterone replacement therapy.
Erythrocytosis Erythrocytosis is a condition where there is an increased amount of red blood cells. These cells carry oxygen from the lungs to tissues and organs. Erythrocytosis may be primary or secondary. Primary erythrocytosis is due to an alteration of hematopoietic progenitor cells, and secondary erythrocytosis is signaling that is inappropriate (PDF). In older men, erythrocytosis is very common. Compared to topical preparations, the injection of testosterone replacement therapy has a higher potential for erythrocytosis. Both hemoglobin and hematocrit increase in a linear manner. Even though this might be helpful for patients who have anemia, the long-term effects are still unknown. According to epidemiological studies, as the levels of hematocrit increase, the higher the risk of mortality and developing cerebrovascular disease. The mechanism for the effect of erythropoiesis on testosterone is still not known. There is controversy on the administration of testosterone replacement therapy since it is believed to have a risk of potential venous thromboembolism (VTE) [98] . It was proposed that due to the secondary blood profile changes, this would cause risk for VTE; however, VTE not correlating with polycythemia and erythrocytosis has doubted this notion [98] . Because the risks that are associated with testosterone replacement therapy are still not known, it is crucial to take notice of the elevated levels of Hb and Hct.
A recent study conducted by Bachman et al. may provide an idea of what the mechanism should be. It was hypothesized that there was a multicomponent system to explain the effects of testosterone replacement therapy [98] . The results indicated that serum EPO levels had significantly increased from baseline into the normal range just after 1 month for the TRT group compared to the control group [98] . The erythropoietin (EPO) levels stayed at constant elevated levels post-HB increase which meant that there was not a negative feedback inhibition. While, the Hb-EPO set point was altered for the TRT group as opposed to the control group [98] . During TRT, the levels of iron metabolism were also altered. Hepcidin, which regulates the entry of iron in the circulation of mammals, was found to be decreased by 49% in the TRT group. Conversely, ironturnover increased which served as a sign of iron-dependent erythropoietitic activity. This lead to increases in Hb and Hct based on the four components [98] . The conclusion that Calado et al. had arrived from these results showed that there would be an increase in transcription based on the influence of estradiol; the estrogen receptor alpha binds to a promotor that is located on the telomerase reverse transcriptase gene. The increased transcription would increase telomerase stability, which would increase hematopoietic stem cell proliferation. There still needs to be larger studies to understand Hb and Hct as side effects of testosterone replacement therapy since the risk of vascular disease is still unclear [98] .
Reduced aromatase levels in hypogondal diabetic men and estrogen and androgen receptors Ghanim et al. observed that in hypogonadal men with type 2 diabetes, the expression of ERalpha and AR receptors in adipose tissue were much lower. Therefore, this indicates that there is a deficiency in mechanisms converting testosterone to aromatase and the ones associated with the estradiol response in ER [99] . There is an intensification of the defect rather than a compensatory response to testosterone deficiency. Testosterone replacement causes an increase in the expression of aromatase, AR, and ERalpha, since it leads to an increase in estradiol and plasma testosterone concentrations. There was also an increase in nuclear protein content of AR in MNCperipheral blood mononuclear cells and expression of AR. The study conducted by Ghanim et al. concluded that testosterone replacement restored AR expression levels to the normal levels in eugondal men [99] . The increase in improved insulin body mass during hyperinsulinemic euglycemic clamp and lean body mass has been caused through enhanced AR levels since the target of testosterone action is skeletal muscle. Estradiol concentrations are decreased due to low testosterone concentrations because of a reduction in the testosterone required for the formation of estradiol. The reduction of estradiol must indicate that there is a dual mechanism. Obese eugondal men have higher estradiol concentrations as compared to obese hypogonadal men. Testosterone concentration in obese and lean men is not definitive of the expression of aromatase in subcutaneous adipose tissue. Furthermore, an impairment of estradiol action will result due to the reduction in the expression of ERalpha.
Since the absence of aromatase is associated with osteoporosis in men, it has been demonstrated that the bone density is determined from estradiol concentrations [99] .
Conclusion
Hypogonadism is common among the male population especially in older men who are obese. The role of aromatase is often overlooked when examining an adult male for obesityassociated hypogonadism. Lack of exercise can influence testosterone levels negatively. Low physiological testosterone levels cause an accumulation of adipose tissue with symptoms of a decrease in bone mineral density and accumulation of fat. The use of testosterone replacement therapy can be addicting and can cause the user to have both physiological and physical withdrawals.
